Exvastat wins a 3.6 million euro grant for COVID-19 trial
Congratulations to Cambridge Innovation Capital portfolio company Exvastat that has been awarded a grant from the prestigious Innovative Medicines Initiative.
The grant will be used to reformulate and study imatinib in the treatment of Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) in collaboration with Vrije Universiteit Amsterdam (VU Amsterdam), KABS Laboratories Inc. and Simbec-Orion.
Read more about the grant and planned trial here.
Want to discover more news? Read how we’re working with Oncodistinct Network.